NeuroPace, Inc. (NPCE)
NASDAQ: NPCE · Real-Time Price · USD
14.54
-0.74 (-4.84%)
At close: Feb 11, 2026, 4:00 PM EST
14.56
+0.02 (0.14%)
After-hours: Feb 11, 2026, 4:32 PM EST
NeuroPace Employees
NeuroPace had 209 employees as of September 30, 2025. The number of employees increased by 25 or 13.59% compared to the same quarter last year.
Employees
209
Change
25
Growth
13.59%
Revenue / Employee
$453,895
Profits / Employee
-$114,766
Market Cap
484.29M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 209 | 25 | 13.59% |
| Jun 30, 2025 | 209 | 30 | 16.76% |
| Mar 31, 2025 | 195 | 14 | 7.73% |
| Dec 31, 2024 | 184 | 13 | 7.60% |
| Sep 30, 2024 | 184 | 15 | 8.88% |
| Jun 30, 2024 | 179 | 10 | 5.92% |
| Mar 31, 2024 | 181 | 18 | 11.04% |
| Dec 31, 2023 | 171 | 4 | 2.40% |
| Sep 30, 2023 | 169 | -5 | -2.87% |
| Jun 30, 2023 | 169 | -18 | -9.63% |
| Mar 31, 2023 | 163 | -12 | -6.86% |
| Dec 31, 2022 | 167 | 1 | 0.60% |
| Sep 30, 2022 | 174 | 9 | 5.45% |
| Jun 30, 2022 | 187 | 28 | 17.61% |
| Mar 31, 2022 | 175 | 22 | 14.38% |
| Dec 31, 2021 | 166 | 14 | 9.21% |
| Sep 30, 2021 | 165 | 13 | 8.55% |
| Jun 30, 2021 | 159 | - | - |
| Mar 31, 2021 | 153 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Varex Imaging | 2,400 |
| Orthofix Medical | 1,616 |
| Bioventus | 950 |
| Standard BioTools | 818 |
| Cytek Biosciences | 692 |
| Cerus | 630 |
| Pacific Biosciences of California | 575 |
| OrthoPediatrics | 562 |
NPCE News
- 4 weeks ago - NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook - Business Wire
- 6 weeks ago - NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy - Business Wire
- 2 months ago - NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy - Business Wire
- 2 months ago - NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting - Business Wire
- 2 months ago - NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services - Business Wire
- 3 months ago - NeuroPace, Inc. (NPCE) Q3 2025 Earnings Call Transcript - Seeking Alpha